Since 2015, with the opening of policies and the rapid flow of talent, funds, and technology, the technological innovation of the Chinese pharmaceutical industry has become increasingly high. Business development capabilities have also matured, evolving from early simple licensing in, followed by rapid market entry or financing and listing through fast-following, to a gradual shift toward a combination of licensing in and licensing out. Chinese pharmaceutical companies fully utilize the high-profit space in foreign markets and the high cost-effectiveness of domestic research and development, optimizing the ecosystem. However, due to the relatively short transition time for the entire international development, limited experience accumulation inevitably leads to various problems. Humphries uses its professional expertise to assist the pharmaceutical industry in avoiding pitfalls in business development.
Competitive Intelligence Compilation
Collecting and compiling competitive intelligence serves as the eye of the entire business development process. Currently, there are several databases on the market to assist companies in collecting information from project initiation to similar projects' patents and development progress. Humphries goes further by tracing primary data, ensuring that we provide clients with more effective regulatory analysis and an in-depth understanding of the current competitive landscape.
Regulatory Assessment and Due Diligence
With over two decades of deep expertise in the regulatory field, Humphries can assist clients in identifying regulatory risks in existing materials within the stipulated time frame. The company can identify potential regulatory obstacles that intended or deliberately concealed projects might face, providing enterprises with a clear understanding of existing risks through one-on-one interviews and meetings.
Strategic Consultation
Combining the project characteristics and regulatory requirements of the client, Humphries fully utilizes tools in international regulations to assist in designing short-, medium-, and long-term drug development strategies. This ensures the development is efficient and aligns with the enterprise's interests, enabling the company to achieve more with less effort.
Document Handover
As the final link in business development, document handover still carries undeniable risks, especially concerning related regulatory communication documents. Humphries adheres to the rigorous style required for registration work, working with technical personnel to comb through the handover documents, ensuring there are no mistakes.
Service